It’s notoriously difficult for doctors to identify a wound that is becoming infected. Clinical signs and symptoms are imprecise and methods of identifying bacteria can be time-consuming and inaccessible, so a diagnosis can be subjective and dependent on clinician experience.
Xeljanz Edges Humira Just a Bit for Real-World RA Patients, Study Suggests
Tofacitinib (Xeljanz) appeared ever-so-slightly more effective than adalimumab (Humira) for rheumatoid arthritis (RA) in a study that used real-world patient data to simulate a randomized
July 1, 2023